## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.7% below STRENGTH zone (3.0-6.0%); PEG 33.66 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.16)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Investors who lost money on Baxter International, Inc.(BAX) should contact Levi & Korsinsky about pending Class Action - BAX**
- Source: WJBF | 20251209T090000 | Neutral | Relevance: 99%
-  Levi & Korsinsky, LLP has announced a class action securities lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of investors who suffered losses due to alleged securities fraud between February 23, 2022, and July 30, 2025. The lawsuit claims Baxter made false statements and concealed systemic defects in its Novum LVP product, leading to malfunctions and patient risks. Investors have until December 15, 2025, to request to be appointed as lead plaintiff.

**2. Baxter International, Inc. (BAX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit**
- Source: PR Newswire | 20251210T170142 | Neutral | Relevance: 99%
-  Glancy Prongay & Murray LLP has announced a securities fraud class action lawsuit against Baxter International, Inc. (BAX) for investors who suffered losses. The lawsuit alleges that Baxter failed to disclose systemic defects in its Novum LVP product, leading to patient harm and misrepresenting the company's business prospects. Investors who suffered losses between February 23, 2022, and July 30, 2025, have until December 15, 2025, to seek to become lead plaintiff.

**3. Baxter International, Inc. (BAX) Investors: December 15, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: ConchoValleyHomepage.com | 20251209T130749 | Neutral | Relevance: 99%
-  Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Baxter International, Inc. (NYSE:BAX) to contact them regarding a securities class action lawsuit. The lawsuit alleges that Baxter made false and misleading statements about systemic defects in its Novum LVP medical device, which caused malfunctions and patient harm. Investors who purchased Baxter common stock between February 23, 2022, and October 29, 2025, have until December 15, 2025, to apply to be a lead plaintiff.

**4. Baxter International, Inc. (BAX) Shareholders Get Answers in Latest SueWallSt Podcast**
- Source: www.yourerie.com | 20251210T130742 | Neutral | Relevance: 99%
- Levi & Korsinsky, LLP has released a podcast discussing a class action securities lawsuit against Baxter International, Inc. (NYSE:BAX). This lawsuit alleges that Baxter made false statements regarding defects in its Novum LVP product, which caused widespread malfunctions, exposing patients to serious risks. The complaint claims Baxter was aware of issues but implemented inadequate remedial measures, impacting the product's safety, efficacy, and sales prospects.

**5. How Investors Are Reacting To Baxter (BAX) Legal Headwinds And Balance Sheet Moves**
- Source: Simply Wall Street | 20251209T062153 | Neutral | Relevance: 99%
-  Baxter International is facing legal challenges from securities class action lawsuits related to alleged undisclosed safety defects in its Novum LVP infusion device. These legal headwinds come as the company makes significant balance sheet moves, including cash tender offers for senior unsecured notes and relaxing net leverage covenants, aiming to manage potential related costs and preserve financial flexibility amidst its margin-recovery strategy. Investors are weighing these new risks against the company's efforts to improve profitability and product reliability.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 33.7x requires aggressive growth execution.
2. Elevated short interest (9.7%): bears positioning against stock.
3. Long-term trend broken: trading 31.7% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 33.66 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.4B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 33.66 |
| Forward P/E | 7.9 |
| Current P/E | 7.7 |
| YoY Growth | -2.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -2.7% (minimal 5-day change). Below STRENGTH zone by 5.7pp (needs >3.0% for momentum thesis). Below SMA200 (0.68x), long-term trend not supportive. RSI neutral at 41.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.68% (CS: 20) | Weak |
| RSI_14 | 41.1 | Neutral |
| MACD Histogram | 0.12 | Bullish |
| vs SMA20 | 0.992x | Below |
| vs SMA50 | 0.902x | Below |
| vs SMA200 | 0.683x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.26
- **Stop Loss:** $17.16 (6.0% risk)
- **Target:** $19.36 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 454
- **Position Value:** $8,290.04
- **Portfolio %:** 8.29%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*